Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMe2209117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autoimmune nodopathies: emerging insights and clinical implications.
Curr Opin Neurol
October 2025
Neuromuscular Diseases Unit, Department of Neurology, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, CIBERER, Barcelona, Spain.
Purpose Of Review: Autoimmune nodopathies (AN) are a recognized distinct group of immune-mediated peripheral neuropathies with unique immunopathological features and therapeutic implications. This review synthesizes recent advances in their pathogenesis, diagnosis, and management, which have refined their clinical classification and informed targeted treatment strategies.
Recent Findings: AN are characterized by autoantibodies targeting surface proteins in the nodal-paranodal area (anti-contactin-1, anti-contactin-associated protein 1, anti-neurofascin-155, anti-pan-neurofascin), predominantly of IgG4 subclass.
Blockade of metastasis by targeting circulating tumor cells with platelet encapsuled oncolytic adenovirus.
Biomaterials
September 2025
Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, PR China. Electronic address:
Host immune elimination largely limits the application of oncolytic viruses in clinics. Here, we rationally design a bioactive platelet-based oncolytic adenovirus delivery system. Upon loading adenoviruses, platelets are transformed to a pro-endocytosis status, which facilitates their internalization by circulating tumor cells (CTCs).
View Article and Find Full Text PDFFactors influencing monoclonal antibody pharmacokinetics across varying immune perturbations.
J Control Release
September 2025
Department of Bioengineering, Rice University, Houston, TX, USA. Electronic address:
The development of continuous-release devices or injectables for the long-term delivery of biologics is of great interest, especially monoclonal antibodies (mAbs) that require frequent, high-dose injections. Preclinical testing of these technologies in murine models is necessary for clinical translation; however, xenogeneic responses to the mAb and foreign body responses to the implants or injectables can confound results. Immune system knockout (KO) models that affect immune cells are often used in these experiments, but the effects of KO models on mAb pharmacokinetics (PK) are not well characterized.
View Article and Find Full Text PDFAssociation between mixed oil lipid emulsions and all-cause infections relative to soybean oil lipid emulsions in hospitalized adults: A retrospective cohort study.
JPEN J Parenter Enteral Nutr
September 2025
Division of Gastroenterology, Department of Medicine, Toronto General Hospital, University of Toronto, University Health Network, Toronto, Ontario, Canada.
Background: Intravenous lipid emulsions are a key component of parenteral nutrition, and their fatty acid compositions may influence immune responses and clinical outcomes.
Methods: This retrospective cohort study conducted from January 2020 to December 2022 compared clinical outcomes of hospitalized non-critical care patients receiving parenteral nutrition with either mixed oil or soybean oil lipid emulsions for at least 48 h. The primary outcome was a composite of the presence of pneumonia, urinary tract infection, or an intra-abdominal collection diagnosed within 14 days of initiating parenteral nutrition.
Utilization of intravenous posaconazole in pediatric patients undergoing hematopoietic stem cell transplant.
Transplant Cell Ther
September 2025
Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Background: Pediatric patients undergoing hematopoietic stem cell transplant (HSCT) are at high risk for fungal infections including Candida, Aspergillus, and Mucorales necessitating the use of broad-spectrum antifungal agents such as posaconazole for prophylaxis and at times for treatment of invasive fungal infections. When first approved, posaconazole was limited to an immediate release oral suspension, which exhibited unreliable absorption dependent on co-administration with high fat meals. During HSCT, patients commonly have significant nausea, vomiting, and decreased enteral intake making this formulation particularly challenging.
View Article and Find Full Text PDF